Skip to main
DRIO

DarioHealth (DRIO) Stock Forecast & Price Target

DarioHealth (DRIO) Analyst Ratings

Based on 3 analyst ratings
Buy
Strong Buy 67%
Buy 0%
Hold 33%
Sell 0%
Strong Sell 0%

Bulls say

DarioHealth is a strong financial investment opportunity due to its impressive revenue and EBITDA growth projections for 2026 and 2027, as well as its unique position in the digital health market with its vertically integrated health intelligence platform and AI-driven recommendations. While there are potential risks associated with industry conditions and customer retention, management has shown strong cost management and a growing pipeline, which should lead to continued success in the enterprise market and overall company growth. Additionally, DarioHealth's recent announcement of a partnership with a hospital system further expands its potential for future revenue growth and innovative solutions in chronic care management.

Bears say

DarioHealth is a digital therapeutics company with a vertically integrated health intelligence platform, offering personalized interventions, hardware devices for physiological data generation, and AI. However, concerns arise from softer revenue performance and potential risks, such as competition. Recent expansions and partnerships show potential for revenue growth, but the company's focus on B2B2C solutions may limit its reach to consumers and lead to slower revenue growth. With the company still not reaching EBITDA breakeven and a high target price based on revenue estimates, the negative outlook stems from uncertainties about the company's ability to achieve sustainable profitability and concerns about its long-term growth potential.

DarioHealth (DRIO) has been analyzed by 3 analysts, with a consensus rating of Buy. 67% of analysts recommend a Strong Buy, 0% recommend Buy, 33% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of DarioHealth and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About DarioHealth (DRIO) Forecast

Analysts have given DarioHealth (DRIO) a Buy based on their latest research and market trends.

According to 3 analysts, DarioHealth (DRIO) has a Buy consensus rating as of Aug 29, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $10, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $10, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

DarioHealth (DRIO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.